Status:
RECRUITING
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Lead Sponsor:
Theravectys S.A.
Conditions:
HPV-Related Cervical Carcinoma
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV). The main q...
Detailed Description
As of 06Nov2025 the recruitment in ARm A of the study (recurrent/metastatic cancers) has been closed to further enrollment, in accordance with the protocol and the study's prespecified operational and...
Eligibility Criteria
Inclusion Criteria:
- histologically confirmed invasive HPV-related oropharyngeal or cervical cancer
- ECOG performance status of 0 or 1
- adequate hepatic, renal, pulmonary, and bone marrow/hematological function
Exclusion Criteria:
- with seropositivity for HIV, active hepatitis C virus (HCV) infection, or hepatitis B (HBV) infection
Key Trial Info
Start Date :
August 8 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT06319963
Start Date
August 8 2024
End Date
December 1 2026
Last Update
February 2 2026
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Florida Cancer Specialists (from Sarah Canon research Institute)
Orlando, Florida, United States, 32827
2
Tampa General Hospital
Tampa, Florida, United States, 33606
3
Moffitt Cancer Center
Tampa, Florida, United States, 33612
4
Oklahoma Cancer Specialists and Research Institute, LLC
Tulsa, Oklahoma, United States, 74146